JP2022515188A5 - - Google Patents

Info

Publication number
JP2022515188A5
JP2022515188A5 JP2021536007A JP2021536007A JP2022515188A5 JP 2022515188 A5 JP2022515188 A5 JP 2022515188A5 JP 2021536007 A JP2021536007 A JP 2021536007A JP 2021536007 A JP2021536007 A JP 2021536007A JP 2022515188 A5 JP2022515188 A5 JP 2022515188A5
Authority
JP
Japan
Prior art keywords
tdsrna
checkpoint inhibitor
checkpoint
use according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021536007A
Other languages
English (en)
Japanese (ja)
Other versions
JP7737143B2 (ja
JP2022515188A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/068044 external-priority patent/WO2020132560A2/en
Publication of JP2022515188A publication Critical patent/JP2022515188A/ja
Publication of JP2022515188A5 publication Critical patent/JP2022515188A5/ja
Application granted granted Critical
Publication of JP7737143B2 publication Critical patent/JP7737143B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021536007A 2018-12-21 2019-12-20 がん治療のための組成物および方法 Active JP7737143B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862783834P 2018-12-21 2018-12-21
US62/783,834 2018-12-21
US201962792760P 2019-01-15 2019-01-15
US201962792765P 2019-01-15 2019-01-15
US62/792,765 2019-01-15
US62/792,760 2019-01-15
US201962869909P 2019-07-02 2019-07-02
US62/869,909 2019-07-02
US201962885143P 2019-08-09 2019-08-09
US62/885,143 2019-08-09
PCT/US2019/068044 WO2020132560A2 (en) 2018-12-21 2019-12-20 Compositions and methods for cancer therapy

Publications (3)

Publication Number Publication Date
JP2022515188A JP2022515188A (ja) 2022-02-17
JP2022515188A5 true JP2022515188A5 (cg-RX-API-DMAC7.html) 2022-12-27
JP7737143B2 JP7737143B2 (ja) 2025-09-10

Family

ID=69326681

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021536007A Active JP7737143B2 (ja) 2018-12-21 2019-12-20 がん治療のための組成物および方法

Country Status (12)

Country Link
US (1) US20220096518A1 (cg-RX-API-DMAC7.html)
EP (1) EP3897854A2 (cg-RX-API-DMAC7.html)
JP (1) JP7737143B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210106531A (cg-RX-API-DMAC7.html)
CN (1) CN113474048A (cg-RX-API-DMAC7.html)
AU (1) AU2019403445A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021012103A2 (cg-RX-API-DMAC7.html)
CA (1) CA3124408A1 (cg-RX-API-DMAC7.html)
MX (1) MX2021007565A (cg-RX-API-DMAC7.html)
NL (1) NL2024544B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202106295WA (cg-RX-API-DMAC7.html)
WO (1) WO2020132560A2 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11813279B2 (en) 2018-12-21 2023-11-14 Aim Immunotech Inc. Compositions for cancer therapy and methods
EP3999645A1 (en) * 2020-09-21 2022-05-25 Aim Immunotech Inc. Compositions and methods for treating cancer
CN119643843B (zh) * 2022-03-15 2025-08-12 上海君赛生物科技有限公司 肿瘤特异性免疫细胞标志物及其用途
CN115645515A (zh) * 2022-12-28 2023-01-31 北京圣美细胞生命科学工程研究院有限公司 肿瘤治疗组合物及应用、药物组合物和细胞生长抑制方法
AU2024283652A1 (en) * 2023-06-05 2026-01-15 Gmp Biotechnology Limited Anti-cancer tgfb2 agents with immunotherapeutics
CN118976108B (zh) * 2024-08-02 2025-04-01 哈尔滨工业大学 一种用于激活抗肿瘤氧化应激和长期免疫反应的聚合前药纳米反应器的制备方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4024222A (en) 1973-10-30 1977-05-17 The Johns Hopkins University Nucleic acid complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5258369A (en) 1988-08-29 1993-11-02 Hem Pharmaceuticals Corporation Treatment of chronic cerebral dysfunction by dsRNA methodology
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
EP0690452A3 (en) 1994-06-28 1999-01-07 Advanced Micro Devices, Inc. Electrically erasable memory and method of erasure
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
PT2231628E (pt) * 2008-01-04 2015-12-29 Gilead Sciences Inc Inibidores de citocromo p450
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
AU2009308105B2 (en) * 2008-10-23 2016-07-07 Aim Immunotech Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
US8722874B2 (en) 2008-10-23 2014-05-13 Hemispherx Biopharma, Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
US20100160413A1 (en) 2008-10-23 2010-06-24 Hemispherx Biopharma, Inc. Double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
US20140170191A1 (en) * 2008-10-23 2014-06-19 Hemispher Biopharma, Inc. Novel double-stranded ribonucleic acids with rugged physico-chemical structure and highly specific biologic activity
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
EP3279215B1 (en) 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
EP2717895A1 (en) 2011-06-08 2014-04-16 Aurigene Discovery Technologies Limited Therapeutic compounds for immunomodulation
WO2013132317A1 (en) 2012-03-07 2013-09-12 Aurigene Discovery Technologies Limited Peptidomimetic compounds as immunomodulators
CN104245726A (zh) 2012-03-29 2014-12-24 奥瑞基尼探索技术有限公司 来自人pd1的bc环的免疫调节环状化合物
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
CN106794246B (zh) * 2014-08-08 2021-10-15 OncoQuest制药有限公司 肿瘤抗原特异性抗体和tlr3刺激以增强检查点干扰癌症疗法的性能
BG111827A (bg) 2014-09-24 2016-03-31 Динко Бахов Метод и устройство за изпридане на прежда от щапелни влакна
GB201503776D0 (en) * 2015-03-05 2015-04-22 Pci Biotech As Compound and method
KR102894264B1 (ko) 2015-03-10 2025-12-02 오리진 온콜로지 리미티드 면역조절제로서의 1,2,4-옥사다이아졸 및 티아다이아졸 화합물
JP2018507885A (ja) 2015-03-10 2018-03-22 オーリジーン ディスカバリー テクノロジーズ リミテッドAurigene Discovery Technologies Limited 免疫調節剤としての1,3,4−オキサジアゾールおよびチアジアゾール化合物
SG11201706901TA (en) 2015-03-10 2017-09-28 Aurigene Discovery Tech Ltd Therapeutic cyclic compounds as immunomodulators
WO2016142894A1 (en) 2015-03-10 2016-09-15 Aurigene Discovery Technologies Limited 3-substituted 1,3,4-oxadiazole and thiadiazole compounds as immunomodulators
EA201791621A1 (ru) 2015-03-10 2018-02-28 Ауриджен Дискавери Текнолоджис Лимитед 3-замещенные-1,2,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
WO2016187656A1 (en) * 2015-05-22 2016-12-01 La Trobe University Method of diagnosis of breast cancer
CA3014759C (en) * 2016-02-15 2020-09-22 FKD Therapies Limited Improved interferon therapy
US20190209669A1 (en) * 2016-08-23 2019-07-11 Oncopep, Inc. Peptide vaccines and durvalumab for treating breast cancer
MX2019002946A (es) * 2016-09-14 2019-09-26 Abbvie Biotherapeutics Inc Anticuerpos anti-pd-1 y sus usos.

Similar Documents

Publication Publication Date Title
CN114127121B (zh) 用于通过cd39表达细胞的adcc靶向促进和增强t细胞介导的免疫反应的方法和组合物
US12559564B2 (en) Compositions and methods for preventing or reversing t-cell exhaustion through ectonucleotidase inhibition and antibody-mediated target cytosis
JP7737143B2 (ja) がん治療のための組成物および方法
US20230086099A1 (en) Combination therapy for treatment of cancer and cancer metastasis
US20240052061A1 (en) Methods and compositions for potentiating antitumoral immune responses through targeting of ntpdase3
WO2023165561A1 (en) Anti-cd39 antibodies and use thereof
JP2026048806A (ja) 細胞傷害性t細胞耐性腫瘍を治療するための組成物および方法
US20210196744A1 (en) Compositions for cancer therapy and methods
JP2025526677A (ja) B7-h3抗原結合性分子
WO2024227030A1 (en) Bcl11b sustains multipotency and restricts effector programs of intestinal resident memory cd8+ t cells
US20240000883A1 (en) Method of sensitizing cancers to immunotherapy using immunomodulatory agents
KR20240099228A (ko) 조작된 nk 세포 및 이의 용도
RU2846282C2 (ru) Способы и композиции для стимуляции и потенцирования опосредованных т-клетками иммунных ответов посредством adcc-нацеливания cd39-экспрессирующих клеток
US20240307335A1 (en) IRG Blockade to Armor CAR T Cells Against Myeloid Dysfunction
US20260069690A1 (en) Novel cd4+ tumor infiltrating lymphocytes for the treatment of cancer
KR20250024750A (ko) 치료용 t 세포 산물
HK40088092A (en) Methods and compositions for potentiating antitumoral immune responses through targeting of ntpdase3
HK40062439B (en) Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells